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Background: There is increasing international recognition that populations included in trials should adequately
represent the population treated in clinical practice; however, adults who lack the capacity to provide informed
consent are frequently excluded from trials. Addressing the under-representation of groups such as those with
impaired capacity to consent is essential to develop effective interventions and provide these groups with the
opportunity to benefit from evidence-based care. While the spotlight has been on ensuring only appropriate and
justifiable exclusion criteria are used in trials, barriers to the inclusion of adults lacking capacity are multifactorial and
complex, and addressing their under-representation will require more than merely widening eligibility criteria. This
commentary draws on the literature exploring the inclusion of adults lacking the capacity to consent in research
and a number of recent studies to describe the methodological, structural, and systemic factors that have been
identified.
Main text: A number of potentially modifiable factors contributing to the under-representation of adults lacking
the capacity to consent in trials have been identified. In addition to restrictive eligibility criteria, methodological
issues include developing appropriate interventions and outcome measures for populations with impaired capacity.
Structurally determined factors include the resource-intensive nature of these trials, the requirement for more
appropriate research infrastructure, and a lack of interventions to inform and support proxy decision-makers.
Systemic factors include the complexities of the legal frameworks, the challenges of ethical review processes, and
paternalistic attitudes towards protecting adults with incapacity from the perceived harms of research.
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Conclusions: Measures needed to address under-representation include greater scrutiny of exclusion criteria by
those reviewing study proposals, providing education and training for personnel who design, conduct, and review
research, ensuring greater consistency in the reviews undertaken by research ethics committees, and extending
processes for advance planning to include prospectively appointing a proxy for research and documenting
preferences about research participation. Negative societal and professional attitudes towards the inclusion of
adults with impaired capacity in research should also be addressed, and the development of trials that are more
person-centred should be encouraged. Further work to conceptualise under-representation in trials for such
populations may also be helpful.
Keywords: Informed consent, Mental capacity, Randomised controlled trials, Inclusion, Underserved populations
Background
Recent efforts to reduce health inequities have failed to
address the significant disparities that persist for some
population groups in accessing high-quality care. One
barrier to achieving health equity is the inadequate re-
cruitment of under-represented and underserved popu-
lations in research [1]. These research inequities
contribute, in part, to the lack of evidence for providing
effective care and treatment, resulting in evidence-biased
care for some groups [2]. There is increasing inter-
national recognition that populations included in clinical
trials should adequately represent the population treated
in clinical practice [3], a position reinforced in the up-
coming Clinical Trials Regulation No. 536/2014 that
states that the participants in a clinical trial should rep-
resent the population groups that are likely to use the
medicinal product investigated in the clinical trial [4].
The lack of representation of certain groups in trial pop-
ulations brings the external validity (the extent to which
the results can be generalised to other circumstances or
populations) [5] of trials into question, which is even
more important when these groups are systematically
excluded from those trials [6, 7]. This has led to major
research funders, such as the UK National Institute for
Health Research (NIHR), to lead projects to address the
challenges of carrying out health research with under-
represented groups (e.g. NIHR INCLUDE [8]) and to
introduce reviews of the suitability of, and justification
for, inclusion and exclusion criteria as part of their re-
view processes [9].
Research involving vulnerable groups, such as adults
lacking mental capacity, raises many ethical and legal is-
sues—particularly with respect to informed consent for
them to be included in a project [10, 11]. As a result, re-
cruitment of vulnerable groups to research is a complex
process [12, 13] and the exclusion of people with cogni-
tive impairment from research is widespread [6, 7]. The
exclusion of those who lack the capacity to consent from
participating in research has been highlighted as a con-
cern in populations where the prevalence of impaired
capacity is high [14] and where less is known about what
works most effectively to improve care [15]. For ex-
ample, the Learning Disabilities Mortality Review
programme found that people with learning disabilities
die, on average, 15–20 years earlier than the general
population, with many deaths being potentially amenable
to health care interventions [16]. People living with a
learning disability have higher rates of long-term health
conditions, such as cardiovascular disease, diabetes and
mental illness, and are more likely to be admitted to
hospital as an emergency [16]. However, there is a lack
of an evidence base for many of the interventions and
treatments provided to people with learning disabilities
[17]. Previous studies have found that over 90% of ran-
domised controlled trials are designed to exclude people
with a learning disability [6]. A recent review of studies
on the NIHR portfolio found that 60% of the studies ex-
cluded learning disability groups, none of the studies in-
vestigating pneumonia or sepsis included learning
disability groups despite being a key contributor to pre-
mature deaths, and only 1.4% of all studies were specific-
ally related to learning disabilities [18]. Similar
exclusions of people with cognitive impairment are seen
in other areas of research such as geriatrics [7], rehabili-
tation interventions following hip fracture [19], peri-
operative medicine [20], trauma [21] and neurological
research [22]. Under-recruitment to research into condi-
tions such as dementia is one of the key challenges to
advancing understanding of these conditions and im-
proving the care and treatment of those who live with
these conditions [23].
With growing evidence of the widespread exclusion of
adults lacking capacity from clinical trials and other re-
search, there have been calls for a review of the ethical
barriers to the inclusion of these populations, and for
greater active involvement of research funding organisa-
tions to scrutinise the justifications behind this exclusion
[18]. However, this issue is more complex than might be
first thought. The recruitment of adults with impaired
capacity is situated within a complex system of factors
[24], and the differences between legal jurisdictions and
how different types of research are governed within
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these jurisdictions adds further complexities [2]. Re-
search governance and funder oversight that focuses on
ensuring that appropriate eligibility criteria are used will
not be effective in increasing inclusivity in trials for
adults who lack capacity unless the wider barriers to in-
clusion are recognised and addressed.
The exclusion of adults who lack capacity has been the
subject of two recent publications in Trials. In the first,
we presented data on the concerningly low number of
trials designed to include adults lacking capacity identi-
fied through an analysis of clinical trials in conditions
commonly associated with cognitive impairment that
were completed in the previous 3 years [25]. The second
was a response to our study, in which Griffiths et al. de-
tailed the practical challenges encountered in developing
their trial involving hard-to-reach groups of people liv-
ing with dementia in the community, and the potential
implications for being able to include those with im-
paired capacity [26]—arguably the hardest of all the
groups to reach. The barriers they described included
gaining a favourable ethical opinion, designing recruit-
ment pathways that ensure people living with dementia
have the opportunity to participate in circumstances
when their cognitive disability might impair their ability
to read or understand an invitation letter, and the chal-
lenges of identifying consultees to be involved in deci-
sions about their participation [26].
This commentary discusses and expands on some of
the issues raised by Griffiths et al., drawing on a non-
systematic review of the literature, experience of con-
ducting trials with populations with impaired capacity
[13, 27, 28], and recent findings from a series of studies
exploring the involvement of adults who lack the cap-
acity to consent [25, 29–32]. The aim is to articulate for
the first time some of the wider methodological, struc-
tural, and systemic barriers to the inclusion of adults
lacking capacity as a first step towards identifying and
addressing some of the potentially modifiable factors.
This is presented from the perspective of trials con-
ducted in the UK, but will have implications and rele-
vance for research conducted in other legal jurisdictions.
Barriers to inclusion in research
Restrictive eligibility criteria
Eligibility criteria are used in trials to recruit participants
that are representative of the patient populations who
will ultimately receive the medication or intervention in
clinical practice, and to ensure the safety and protection
of participants [33]. However, some trials use very re-
strictive eligibility criteria that exclude groups without
valid reasons resulting in research samples that do not
represent the diversity, symptom complexity or daily
challenges of the clinical population [22]. This negatively
impacts on the external validity of the trial [33].
Excluding patients with cognitive impairments who are
unable to provide consent is common, although justifica-
tion is rarely provided or discussed as a potential limita-
tion of the trial findings [6, 7, 22]. While eligibility is an
essential component of trial design, arbitrary exclusion
of large numbers of the clinical population restricts the
pool of potential participants, affects the generalisability
of the results and, as these excluded individuals are dis-
proportionately from vulnerable populations, raises eth-
ical concerns [22]. The lack of inclusion of adults who
lack capacity in trials that are directly relevant to them
should be carefully scrutinised by funders and those de-
termining the scientific merit of proposed trials and,
where they are excluded, an evidence-informed justifica-
tion for their exclusion should be explicitly stated [19].
Complexities of legal frameworks
The legal frameworks that govern research involving
adults who lack capacity to consent varies between legal
jurisdictions, even within countries, and in different
types of trials depending on whether the intervention is
an investigational medicinal product or not [2]. These
complexities impact on the ability to conduct studies in-
volving adults lacking capacity. For example, two separ-
ate regulatory regimes govern research involving adults
who lack capacity to consent in England and Wales,
where the Mental Capacity Act 2005 governs how adults
lacking capacity can be involved in research considered
invasive [34]; however, clinical trials of investigational
medicinal products (CTIMPS) are separately regulated
by the Medicines for Human Use (Clinical Trials) Regu-
lations 2004 [35]. There are significant differences be-
tween these regulatory frameworks, including the level
of risk permitted, who acts as proxy decision maker,
how much information is provided to the person lacking
capacity, and whether or not they retain the power of
veto [2]. The impact of different legal arrangements was
demonstrated in our recent clinical trial conducted in
care homes in which we found that the process for set-
ting up a CTIMP in care homes was more complex and
time consuming than the process for setting up an ob-
servational study in the same setting or setting up
CTIMPs in other health care settings [13]. Other juris-
dictions within the UK (Scotland and Northern Ireland)
have different legislation governing research involving
adults with incapacity, and there is a similarly problem-
atic ‘patchwork of legislation’ within Australia [36], the
US [37] and the EU [38]. One EU-wide study to investi-
gate the epidemiology and genetics of sepsis in critical
care patients found that the outcomes when seeking eth-
ical approval differed widely between countries because
of differences in national legislation, and within coun-
tries because of interpretation of the ethics of conduct-
ing research with people lacking capacity [39].
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A number of studies have found a widespread lack of
knowledge and understanding about the legal frame-
works by health care professionals and researchers, in-
cluding in the UK [29], US [40], and Canada [41],
leading to calls for greater education and awareness
about the legal frameworks. The UK survey I led found
that health and social care professionals caring for popu-
lations who lack capacity did not understand that
decision-making processes about research participation
differed from usual care and treatment decisions (re-
search decisions are based on the person’s ‘presumed
will’ and not what was in their best interests), differed
between different types of research (a legal representa-
tive provides consent for CTIMPs whereas a consultee
merely provides advice to researchers for other types of
studies), and who could act as a personal legal represen-
tative or consultee (family members regardless of any
legal arrangements such as having Power of Attorney, or
someone such as themselves acting in a professional
capacity in the absence of a family member or friend)
[29]. Our recent research found similar misconceptions
and misunderstandings were evident in study documents
that had been designed by trial teams and undergone re-
view by research ethics committees (RECs) and received
a favourable opinion [30]. A number of trial information
sheets contained inaccurate interpretations of the legal
frameworks, including who could act as proxy decision-
maker (e.g. holder of Power of Attorney), the basis for
their decision (e.g. best interests), the role title and basis
(e.g. consultee providing consent rather than advice),
and conflated professionals’ clinical and representation
roles [30]. We concluded that there is a need for educa-
tion and training interventions to inform and support
those who design and conduct research studies that in-
clude adults lacking capacity, as well as RECs responsible
for the ethical review of such studies [30].
Ethical review processes
Research ethics has historically been concerned with the
protection of ‘vulnerable groups’ from participation in
research [42]. By contrast, there has been much less con-
cern about ensuring that these groups are not denied
the opportunity to receive the potential benefits of par-
ticipation that are available to others, which may lead to
harm for these groups through being denied the oppor-
tunity to benefit from scientific advances and receive
evidence-based care. The recent update of international
ethics guidelines (from the Council for International Or-
ganizations of Medical Sciences), where there is now a
need to justify exclusion [43], has been seen as marking
a paradigm shift from overprotection to inclusion [44].
However, this is yet to be reflected in the legal frame-
works, and many researchers’ experiences of ethical re-
view processes demonstrate the challenges of justifying
the inclusion of adults who lack capacity in trials and
other studies in practice.
The letter by Griffiths et al. published recently in Tri-
als highlighted the challenges that studies designed to
include adults who lack capacity encounter when seek-
ing a favourable opinion from an REC [26]. The authors
described a lack of awareness from the REC of the im-
portance of including people who lack capacity in the
development phase of a complex intervention (in this
case a primary care-based support intervention for
people living with dementia) to ensure that the interven-
tion was appropriately designed for those who may
benefit most from the intervention [26]. They called for
improvements in the consistency of interpretation and
advice from RECs so that hard-to-reach groups are en-
abled to take part in intervention development research
[26]. There are also published accounts of a lack of
consistency when studies are reviewed by National
Health Service RECs, including how the requirements of
the Mental Capacity Act 2005 are interpreted (e.g.
whether the research is connected to an impairing con-
dition or not), ambiguities about who can act as a nomi-
nated consultee (if a paid carer is permissible or not),
and the ‘grey area’ of when treatment being evaluated is
needed in a timely manner but is not an emergency [45].
A 2009 study reviewed REC reviews of studies involving
adults who lacked capacity and found inconsistency in
the interpretation of legal requirements, the use of in-
correct terms, and the potential to exclude people who
were eligible to be consulted about the involvement of
adults who lack capacity [46]. The authors called for im-
proved clarity, explicitness and accuracy when submit-
ting and reviewing applications for ethical review of
research in this area [46]. Our recent content analysis
found similar issues with study documents that had
undergone review by RECs and received a favourable
opinion [30], suggesting that little has changed in the
intervening decade and that the need for greater clarity
and accuracy remains. While the Health Research Au-
thority, which oversees RECs in the UK, are taking mea-
sures to address inconsistency in ethical reviews [47]
this does not specifically apply to research involving
adults lacking capacity.
Challenges of proxy decision making
For adults who lack the capacity to consent to research,
an alternative proxy or surrogate decision-maker is in-
volved in the decision about their participation. The
legal provisions for who can act as a proxy differ be-
tween legal jurisdictions and the type of research in-
volved, including whether it is emergency research [2].
This presents a number of challenges, including proce-
dures for assessing decision-making capacity, identifying
and approaching proxies, and proxy decision-making
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processes. Trials involving adults lacking capacity are ne-
cessarily resource-intensive, given the skills and time re-
quired to: identify potential participants who are unlikely
to be recruited through traditional methods such as
responding to advertisements; build a relationship with
the potential participant; determine eligibility and pro-
vide tailored information about the trial; sensitively con-
duct capacity assessments; identify suitable proxies who
are able and willing to be involved; provide them with
information about the trial; and seek their consent or
agreement. These vital activities will require additional
resources, recruitment periods, and skilled personnel
that are likely to result in more costly and lengthy trials
than those solely recruiting adults with the capacity to
consent. Processes for recruiting adults who lack cap-
acity are more complex and time consuming, and often
occur outside established and traditional trial settings
[27, 28]. Research infrastructure that supports trials and
other research routinely conducted in health care set-
tings may not be appropriate for trials that include pop-
ulations where capacity is impaired in health and social
care settings without additional training and resources.
This may be additionally so for emergency research
where recruitment is time critical, and models of con-
sent such as deferred consent require ongoing capacity
assessments and approaching participants and/or proxies
for consent at later time points. Research funders should
bear these additional requirements in mind when
reviewing funding applications for trials that include
adults lacking capacity.
Improving informed consent processes for clinical tri-
als has been the focus of much attention in recent times,
with numerous interventions to improve the provision
of information [48], participant understanding [49], and
decision making about participation [50]. Despite the
additional complexity of proxy decisions about participa-
tion made on behalf of an adult who lacks capacity, and
how the person’s preferences and wishes can best be
respected, there has been little research in this area. Our
research has identified the emotional and decisional bur-
dens experienced by proxies making decisions about re-
search [31], and developed the first intervention to
support family members acting as proxies [24]. However,
more research is needed to explore the experiences and
support needs of family members and others acting as
proxies (e.g. health care professionals in the absence of
family members) and those who recruit adults lacking
capacity in different settings. Extending the legal provi-
sions to enable the prospective appointment of a re-
search proxy prior to a loss of capacity, and a formal
process for documenting preferences about participating
in trials in the event of a loss of capacity, may also help
proxies to make decisions that better reflect the prefer-
ence and wishes of the person they represent [32, 51].
Paternalistic attitudes to protection from research
Ensuring the protection of the groups considered most
vulnerable to potential harm is an important aim of re-
search ethics, and also those with professional responsi-
bility to care for groups unable to protect their interests
through informed consent. However, our survey of
health and social care professionals, which explored their
knowledge about the legislation governing research in-
volving adults lacking capacity, revealed a deeper and
more worrying issue about their attitudes towards the
inclusion of people with impaired decision-making cap-
acity in medical research [29]. A number of participants
stated that people who lack capacity should never be in-
cluded in research, both from an ethical and a legal per-
spective, and some voiced concerns that only the
person’s medical practitioner or an appointed judge
should have the authority to decide about research par-
ticipation, and only when it is determined to be in their
best interests to take part [29]. There was a widespread
lack of understanding that the decision about research
participation should not be based on a determination of
best interests [52] and should instead be based on what
the person’s wishes and feelings about taking part would
be, which can only be determined through consulting
with those that know them well. This paternalistic ap-
proach, which positions health and social care profes-
sionals as the ‘gatekeepers’ to research [53], is often
reported anecdotally and creates an additional barrier to
research for those who would have wanted to participate
and those conducting inclusive trials. There is a need for
a sea change in attitudes and greater understanding that
people who lack capacity should have equitable oppor-
tunities to be able to access research studies and to con-
tribute to scientific knowledge in order for them to
receive evidence-based care [53].
Methodological challenges
Trials involving adults lacking capacity can be methodo-
logically challenging; challenges include the difficulties
of developing (or adapting) complex interventions [54],
evaluating interventions [55] (including developing a
common protocol for use in different jurisdictions [39]),
the lack of appropriate outcome measures, and the chal-
lenges of ensuring intervention fidelity [17]. However,
the frequent exclusion of this group from research has
led to Age UK describing them as living in a ‘knowledge
shadow’ [56]. There is an increasing focus on using an
equity lens to critically review the development and
evaluation of health (and other) interventions for popu-
lations who may experience health inequities to ensure
that the evidence generated is of relevance for both clin-
ical practice and public policy making [57]. The lack of
equity in trials of interventions, such as rehabilitation in-
terventions after hip fracture, for adults who lack
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capacity has been identified as a result of their exclusion
from trials [19] based on equity factors (e.g. PROGRESS+
factors [57]). This is due in part to the challenges of con-
ducting trials in settings where there is a high prevalence
of impaired capacity, and which may be in settings where
research is rarely conducted [13, 19, 27, 28]. This may be
further compounded by the challenges raised by a lack of
validated outcome measures for use in trials involving
adults lacking capacity (for example, there are few mental
health measures for people with severe and profound
intellectual disabilities [58]) and the feasibility of using
existing outcome measurement tools [19]. Cognitive im-
pairment may mean that collecting self-reported out-
comes, such as quality of life measures such as the five-
level EuroQol five dimensions questionnaire, is challen-
ging in some groups such as care home residents [59].
While work is ongoing to establish the reliability of proxy-
reported versions of some such measures [59], the limited
range of appropriate and validated measures in these pop-
ulations will inevitably limit the ability to evaluate the ef-
fectiveness (and cost effectiveness) of interventions.
Lack of ‘person-centred’ approaches in trials
The disconnect between established approaches to pro-
viding care for populations who lack capacity, and ap-
proaches to the design and conduct of trials involving
them, creates a conflict between the care and clinical
trial paradigms that acts as a barrier to their inclusion
[60]. Person-centred approaches to health care focus on
flexibility and relationality through treating people as in-
dividuals, respecting their rights as persons, building
mutual trust and understanding, and developing rela-
tionships [61]. In stark contrast, there is little explicit at-
tention paid to the concept of person-centredness in
trials involving these same populations [62]. Researchers
conducting trials with adults with intellectual disabilities
and/or autism identified the need to embrace a range of
person-centred approaches, particularly around consent
processes, to ensure trials are more inclusive [60].
Adopting these approaches, particularly the tailoring of
information provision and consent processes, the use of
decision aids and visual aids to improve cognitive acces-
sibility, and revisiting consent after data collection, are
key to successful trials involving adults lacking capacity
[60]. A framework for person-centred research has been
proposed that aims to move beyond traditional research
governance approaches to consent which focuses on the
‘protection of vulnerable people’ and the signing of a
consent form [62]. Long established practices such as
person-centred approaches to inclusionary consent with
people living with dementia [63], and inclusive ap-
proaches to accessible information and supportive com-
munication widely used with people with learning
disabilities, should be adopted. However, person-centred
approaches necessitate long-term and sustained involve-
ment from researchers [62], which requires additional
resources and greater recognition that simplified
accrual-based metrics may act as a barrier to recruiting
participants with more complex cognitive and communi-
cation needs. It may also require a flexible approach to
the way participation is negotiated and data are collected
[62]. While person-centred principles may be challen-
ging to integrate with the methodological rigor required
when conducting randomised controlled trials, novel ap-
proaches to developing person-centred and randomized
controlled trials are in the early stages of development
[64] and may warrant further attention.
Conclusions
Adults lacking capacity to consent are frequently ex-
cluded from trials, which impacts on the generalisability
of the results to these groups and denies them the op-
portunity to participate and to benefit from evidence
generated through trials. In part, this exclusion is a re-
sult of overly restrictive eligibility criteria, which has re-
ceived the greatest attention from funders; however, a
number of systemic and structural barriers to the inclu-
sion of adults who lack capacity have also been identi-
fied. Addressing these complex issues will be vital if this
under-represented and underserved group are to receive
evidence-based interventions and care that are available
to other population groups. As this is the first attempt at
describing the known barriers to their participation, the
barriers described here do not form an exhaustive list,
nor are the categories to which they have been assigned
(methodological, systemic and structural) considered ab-
solute. Further work to develop this conceptualisation of
under-representation in trials for such populations
should be considered.
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